Farxiga approved to reduce risk for CKD progression
(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.
- Next story Investigating the role of Brd4 in diet-induced obesity
- Previous story HPV vaccination rates suboptimal within ages 9 to 12 years
Explore more
- A new bacteria, made in Belgium
Researchers led by Patrice Cani, FNRS researcher at University of Louvain (UCLouvain)... - Lesbians in Ballet: ‘Has Anyone Like Me Ever Walked These Halls?’
Ballet’s strict gender norms put pressure on women to conform. But dancers... - Get 30-Day Free Access to a Udacity Nanodegree Program & Start Learning for Free
FYI: Until May 23, you can have 30-day free access to a... - WHO panel OKs emergency use of China’s Sinopharm vaccine
The World Health Organization gave emergency use authorization Friday to a COVID-19... - Italy passes 30 million vaccine dose milestone
Italy on Saturday passed the milestone of 30 million doses injected in... - Americans are increasingly experiencing chronic pain
Americans are in chronic pain, and a comprehensive new study exploring trends... - The Next Level in Office Amenities: Wild Horses
The mustangs at a Nevada office park are an example of the... - Resident Evil Village director doesn’t rule out more Lady Dimitrescu
Resident Evil Village director Morimasa Sato explains the origins of Lady Dimitrescu... - Trial tests intervention to reduce sedentary time in patients with kidney disease
A recent randomized trial tested an intervention to reduce sedentary time and... - Good results with online CBT for mental health effects of atopic eczema
The common skin disease atopic eczema (AE) impacts heavily on the life...